2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168652
    4-PivO-NMT chloride 3019920-38-5
    4-PivO-NMT chloride is an indole-derived AMPK signaling pathway modulator that regulates neurogenesis or neurite outgrowth by modulating AMPK activity. 4-PivO-NMT chloride holds promise for research in the fields of neurological disorders, pain, and inflammation.
    4-PivO-NMT chloride
  • HY-168709
    Nrf2 activator 18
    Nrf2 activator 18 (Compound 11a) is an orally active activator for Keap1/Nrf2/HO-1 signaling pathway, that promotes the Nrf2 nuclear translocation, and enhances the antioxidant efficacy. Nrf2 activator 18 inhibits the release of IL-6 with an IC50 of 4.816 μM. Nrf2 activator 18 exhibits anti-inflammatory efficacy in mouse PM2.5-induced lung injury model.
    Nrf2 activator 18
  • HY-168719
    PPARγ agonist 16 2218046-01-4
    PPARγ agonist 16 (Compound 4G) is the agonist for PPARγ, that competitively binds to LBD domain of PPARγ with IC50 of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model.
    PPARγ agonist 16
  • HY-168734
    CB2 receptor agonist 9 2374894-21-8
    CB2 receptor agonist 9 (Compound 33) is an orally active agonist for cannabinoid receptor 2 (CB2 receptor) with an EC50 of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model.
    CB2 receptor agonist 9
  • HY-168737
    NEK7-IN-2
    NEK7-IN-2 (compound 23) is a potent inhibitor of NLRP3-NEK7 interaction. NEK7-IN-2 can enhance the thermal stability of NEK7 and regulatie NLRP3 inflammasome assembly. NEK7-IN-2 inhibits IL-1β releases.
    NEK7-IN-2
  • HY-168764
    C16 Galactosylceramide 34324-89-5
    C16 Galactosylceramide is a sphingolipid compound. C16 Galactosylceramide participates in the physiological processes of lipid metabolism and immune regulation in cells. C16 Galactosylceramide can be used in the study of diabetes.
    C16 Galactosylceramide
  • HY-168841
    p38α-MK2-IN-1 3031770-03-0
    p38α-MK2-IN-1 (Compound 36) is a p38α-MK2 complex inhibitor (IC50: 5 nM). p38α-MK2-IN-1 has a robust inflammation inhibitory effect and joint repair ability.
    p38α-MK2-IN-1
  • HY-168846
    CDK8/19-IN-3
    CDK8/19-IN-3 (compound 3-7) is a potent and selective CDK8 and CDK19 inhibitor. CDK8/19-IN-3 upregulates IL-10 levels. CDK8/19-IN-3 has the potential for the research of inflammatory bowel disease (IBD).
    CDK8/19-IN-3
  • HY-168888
    COX-2-IN-52
    COX-2-IN-52 (Compound 5l) is an orally active and selective COX-2 inhibitor with an IC50 of 54 nM. COX-2-IN-52 can inhibit the release of NO in cells and has anti-inflammatory activity. COX-2-IN-52 has high gastrointestinal safety and can be used in the research of oral anti-inflammatory drugs.
    COX-2-IN-52
  • HY-168922
    Keap1-Nrf2-IN-25
    Keap1-Nrf2-IN-25 (Compound 19) is a potent Keap1-Nrf2 inhibitor (IC50 of 0.55 μM) with Keap1 binding affinity (Kd of 0.50 μM). Keap1-Nrf2-IN-25 activates Nrf2, reduces ROS and pro-inflammatory cytokines (IL-1β, IL-6). Keap1-Nrf2-IN-25 exerts protective effects against DSS (HY-116282)-induced colitis.
    Keap1-Nrf2-IN-25
  • HY-168930
    ATX inhibitor 25 2951100-44-8
    ATX inhibitor 25 (Compound 29) is an orally active Autotaxin inhibitor with an IC50 of 1.08 nM. ATX inhibitor 25 exhibits excellent in vitro metabolic stability, with a t1/2 of more than 170 minutes. In the bleomycin (HY-108345)-induced pulmonary fibrosis mouse model, orally administered ATX inhibitor 25 shows anti-fibrotic effects.
    ATX inhibitor 25
  • HY-168935
    Anti-inflammatory agent 95
    Anti-inflammatory agent 95 (Compound 2e) is an anti-inflammatory agent that exhibits the most potent anti-inflammatory activity in LPS (HY-D1056)-induced RAW 264.7 mouse macrophages. It significantly inhibits the production of NO, with an IC50 of 8.8 μM, and reduces the secretion of TNF-α and IL-1β, with inhibition rates reaching 60% and over 90%, respectively, at a concentration of 100 μM. Anti-inflammatory agent 95 holds promise for research in the field of inflammatory diseases.
    Anti-inflammatory agent 95
  • HY-168952
    GHN105
    GHN105 is an orally active inhibitor for STING that inhibits STING-dependent IFN-β secretion in THP-1 human monocytes with an IC50 of 4.4 μM. GHN105 reduces the IFN-β, IL-6 and CXCL10 levels in serum, and alleviates colitis in DSS (HY-116282)-induced acute colitis mouse model. GHN105 exhibits good pharmacokinetic parameters in mice with an oral bioavailability of 43% and a half-life of 1.1 hours.
    GHN105
  • HY-168954
    CSF1R-IN-26
    CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22%.
    CSF1R-IN-26
  • HY-168963
    PROTAC BTK Degrader-13
    PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for BTK with a DC50 of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of BTK with an IC50 of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway. (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))
    PROTAC BTK Degrader-13
  • HY-168971
    Paeoniflorin-6′-O-benzene sulfonate 1390658-79-3
    Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model.
    Paeoniflorin-6′-O-benzene sulfonate
  • HY-168974
    Fosizensertib 2905377-00-4
    Fosizensertib is the inhibitor for RIP-1 kinase and can be used in researchs of ulcerative colitis.
    Fosizensertib
  • HY-168975
    Fosrugocrixan 2408145-38-8
    Fosrugocrixan is an antagonist for CX3C chemokine receptor 1 (CX3CR1) that exhibits anti-inflammatory activity.
    Fosrugocrixan
  • HY-168981
    Larubrilstat 2765226-31-9
    Larubrilstat is a vascular non-inflammatory molecule-1 (VNN1) inhibitor.
    Larubrilstat
  • HY-168984
    Milpecitinib 1415819-54-3
    Milpecitinib (Compound 21a) is a potent, selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory activity. Milpecitinib is promising for research of cancers and inflammatory disorders.
    Milpecitinib
Cat. No. Product Name / Synonyms Application Reactivity